AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Soliris (eculizumab) — US YoY by Year
Soliris (eculizumab) — US YoY (%) (%)
AstraZeneca Soliris (eculizumab) — US YoY: -28.0% in FY2025, down 16.0 pts from a year earlier.
Latest, FY2025
-28.0%
Period ended Dec 31, 2025
Change on a year earlier
-16.0 pts
-12.0% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Soliris | 1,837 | (29) | (28) | 1,092 | (28) | 405 | (9) | (1) | 200 | (52) | (53) | 140 | (32) | (31)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Soliris (eculizumab) — US YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -28.0% | -16.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | -12.0% | +8.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | -20.0% | -13.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -7.0% | -11.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 4.0% | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Soliris (eculizumab) — US YoY (%), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-soliris-us-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.